The Spanish Association of Cancer Research recognizes his work and grants him the ASEICA Young Investigator Award 2018.
The award ceremony will be held in Valencia on 6, 7 and 8 November.
The Spanish Association for Research on Cancer (ASEICA) has announced the winners of the 2018 ASEICA Awards, among them Roger Gomis, head of the Growth Control and Metastasis lab at IRB Barcelona, who has received the Young Investigator Award in acknowledgement of his work on cancer.
ICREA researcher Roger Gomis leads a multidisciplinary lab devoted to metastasis research at IRB Barcelona. His work focuses on the identification and functional validation of the mechanisms that allow breast and colon cancer to metastasize to clinically relevant sites, and he has published various important articles in recent years.
“These awards aim to acknowledge the magnificent work that Spanish scientists are doing in spite of insufficient resources in the country,” said Carlos Camps, president of ASEICA.
The projects of the awardees will be presented in Valencia on 6,7 and 8 November in a gathering that will serve to disseminate advances in cancer research, present the most recent studies in the field, and showcase the work being undertaken on different types of tumour.
More information: http://www.aseica.es/
This research will help to identify those genes that play a key role in the initiation of metastasis
Metastasis causes 90% of cancer related deaths
TV3’s programme “Els Matins” has interviewed Francesc Posas, director of IRB Barcelona, about the increase in donations given to NGOs and research centres in Catalonia and about the #Metastasis Challenge campaign. During the interview, he talked about the importance of small fundraising initiatives undertaken by individuals, such as that of Magdalena Socias, a cancer patient who has decided to join the challenge by walking the Sierra de Tramontana to give visibility to the fight against metastasis.
Many treatments against cancer, such as TRAIL, aim to trigger a type of cell death known as apoptosis.
A team at IRB Barcelona, headed by Antonio Zorzano, has demonstrated that the protein TP53INP2 induces apoptosis in chemotherapy treatments.
